---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-194427"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:14:26.001254+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end

## Summary
- Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).
- Net income $23.8M ($0.15 basic EPS) vs net loss $32.6M in Q2 2023; includes $44.7M non-cash gain on debt extinguishment.
- Raises FY2024 total revenue guidance low end to $145M from $140M; lowers R&D/SG&A expense guidance to $250-265M from $260-280M.
- Phase 3 SENTRY (myelofibrosis) top-line data on track for 2H 2025; XPORT-EC-042 (endometrial) top-line delayed to early 2026 due to screen failures.
- Debt refinancing extended majority of maturities to 2028/2029; cash $152.5M; cash runway into Q1 2026 (excl. $49.5M debt payments).

## SEC filing metadata
- accession: 0001193125-24-194427
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/0001193125-24-194427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524194427/d878101d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-194427
- JSON: https://secwatch.observer/filing/0001193125-24-194427.json
- Plain text: https://secwatch.observer/filing/0001193125-24-194427.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.